曲美他嗪联合瑞舒伐他汀对冠状动脉慢血流患者血管内皮功能的影响  

Effect of trimetazidine combined with rosuvastatin on vascular endothelial function in coronary slow flow patients

作　　者：吴彩云[1] 王高明[1] 孙志刚[1] WU Caiyun;WANG Gaoming;SUN Zhigang(Department of Cardiology, the First People’s Hospital of Fuzhou,Jiangxi Fuzhou 344000,China)

机构地区：[1]江西省抚州市第一人民医院心内科

出　　处：《上海医药》2019年第17期25-27,共3页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:探究冠状动脉慢血流(CSF)患者采用曲美他嗪、瑞舒伐他汀联合治疗对血管内皮功能的影响。方法:选取100例CSF患者,随机将其分为对照组和研究组各50例。对照组给予瑞舒伐他汀治疗,研究组给予曲美他嗪、瑞舒伐他汀联合治疗,治疗3个月,比较两组的疗效。结果:研究组总有效率和肱动脉血管内皮依赖性舒张功能(FMD)明显优于对照组;患者的血管内皮素-1(ET-1)、超敏C反应蛋白(hs-CRP)水平均低于对照组,且一氧化氮(NO)水平明显更高(P <0.05)。两组不良反应发生率比较差异无统计学意义。结论:对CSF患者采用曲美他嗪、瑞舒伐他汀联合治疗能有效改善其血管内皮功能,安全可靠。Objective: To investigate the effects of trimetazidine combined with rosuvastatin on vascular endothelial function in coronary slow flow (CSF) patients. Methods: One hundred cases of CSF patients were selected and randomly divided into a control group and a study group with 50 cases each. The control group was treated with rosuvastatin while the study group was treated with trimetazidine and rosuvastatin, and the treatment was lasted for 3 months. Therapeutic effects were compared between the two groups. Results: The total effective rate and endothelium-dependent diastolic function (FMD) of brachial artery were significantly better, the levels of endothelin-1 (ET-1) and hypersensitive C-reactive protein (hs-CRP) were lower and nitric oxide (NO) level was significantly higher in the study group than the control group (P<0.05). There were no significant differences in adverse reactions between the two groups (P>0.05). Conclusion: Rimetazidine combined with rosuvastatin in the treatment of CSF patients can effectively improve vascular endothelial function with better safety and reliability.

关 键 词：冠状动脉慢血流 曲美他嗪 血管内皮功能 瑞舒伐他汀 

分 类 号：R972.3[医药卫生—药品] R541.4[医药卫生—药学]